SOURCE: HCi Viocare

HCi Viocare

HCi Viocare

February 08, 2016 12:35 ET

HCi Viocare Is Honored in the Global Digital Health 100 Award List

GLASGOW, UNITED KINGDOM--(Marketwired - Feb 8, 2016) - UK-based bio-engineering company and subsidiary of HCI Viocare (OTCQB: VICA), HCi Viocare Technologies, the developers behind the Smart Insole that monitors diabetic feet, is included in the Global Digital Health 100 Award List, recognized as one of the most innovative and effective companies from around the world, operating in the mobile, digital and connected care industries today.

Reflecting the growing prominence of mobile, digital and connected solutions in the healthcare sector, the Global Digital Health 100 acknowledges the significant work being carried out by organizations from around the globe. This year's list similarly recognizes an industry that is showing the signs of early maturity.

The Global Digital Health 100 represents 6 months of analysis by the editorial and advisory team at the Journal of mHealth, who consider the offerings and innovations from companies across the digital health ecosystem, prior to selecting the final 100. The judging criteria analyses 10 different quantitative and qualitative evaluation metrics including: disruptive impact; proof of concept; technology innovation; social value; effectiveness; execution of strategy; and, industry integration. The selected 100 companies demonstrate true innovation and the opportunity to disrupt the delivery of healthcare at scale.

HCi Viocare's pressure and shear sensing technology has been a groundbreaking innovation initially addressed to diabetics, aiming at preventing foot or toe amputation. Its first application, the Smart Insole, was designed to help diabetes patients make informed decisions about the levels of activity that are appropriate for them, in order to protect their feet's safety, while performing their everyday routine.

The technology uses a multitude of tiny sensors to detect pressure and shear providing on demand information wirelessly. The uniqueness of the HCi Viocare sensing technology consists of its affordability, overcoming of obstacles like heat and humidity that negatively impact other sensing technologies, and its incomparable flexibility and adaptability to different applications.

The high interest shown by prospective partners for the Company's technology after its initial application to the diabetic insole drove HCi Viocare to develop further applications in areas such as the smart active mattress, the smart insole for athletes, the smart wheelchair cushion, the smart automotive seat and many others.

Dr. Christos Kapatos, HCi Viocare's co-founder and CTO stated, "It is a great honor and a significant reward for us to be included in this year's Global Digital Health 100 Award List. It is a real acknowledgment of our continuing efforts to develop cutting edge technology that can empower people with important information. Our commitment is to support the improvement of people's health and wellbeing, and to elevate their everyday experience by delivering solutions that will become affordable, highly innovative products."

Facts and Figures (mHealth Journal)

Global Review Process
10 different assessment criteria
8 categories
From 15 different countries
Categories
Healthcare Applications
Clinical Solutions
Wearable Technologies
Medical Devices
Hardware
Assistive Technologies`
Telehealth/Telecare
Data Analytics
By Region
53 North America
40 Europe
7 Rest of the World
Further info on http://goo.gl/OHK62p

About HCi Viocare Technologies
The company is a Glasgow-based subsidiary of HCi Viocare, which has a dual, complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a portfolio of biomedical technologies to address unmet needs in the diabetic foot, P&O and other health & wellbeing areas, for licensing to established industry participants. HCi Viocare is listed in the OTC Markets in the USA, has its executive office in Athens, Greece and R&D centre in Glasgow, UK.

Please visit: www.hciviocare.com

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company has only recently acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies, including a "smart insole" with several potential applications. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or that it will find suitable commercialization partners for its technologies. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

Contact Information